Posted by Michael Wonder on 02 Mar 2022
BeiGene hits major milestone with first PBS approved cancer treatment
1 March 2022 - BeiGene is welcoming the listing of Brukinsa (zanubrutinib), a targeted treatment for mantle cell lymphoma, an aggressive and rare type of non-Hodgkin’s lymphoma, on the PBS
The listing will lead to improved access to the medicine from 1 March 2022 and is the first therapy from BeiGene to be subsidised by the Australian Government.
